We are live on ! Find out more
BCTXZ

BriaCell Therapeutics Corp Warrant
BCTXZ

4 hedge funds and large institutions have $434K invested in BriaCell Therapeutics Corp Warrant in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more capital invested

Capital invested by funds: $311K → $434K (+$123K)

33% more funds holding

Funds holding: 3 → 4 (+1)

23.94% more ownership

Funds ownership: 39.44% → 63.37% (+24%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$40.4K
2
UBS Group
UBS Group
Switzerland
-$23
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Empery Asset Management
New York
$193K +$248K +666,600 New
HCM
2
Heights Capital Management
California
$163K – – –
SM
3
Sabby Management
Florida
$77.2K -$40.4K -108,524 -29%
UBS Group
4
UBS Group
Switzerland
$1 -$23 -61 -92%

BCTXZ Hedge Fund Activity: Q4 2025 in Review

4 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXZ) for Q4 2025, worth a combined $434K — up 39% from $311K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BCTXZ positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest seller was Sabby Management, cutting an estimated $40.4K.

  • 4 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXZ) as of Q4 2025, up from 3 in Q3 2025.
  • Funds reported $434K of BriaCell Therapeutics Corp Warrant stock for Q4 2025, up 39% quarter-over-quarter.
  • 1 fund opened new BriaCell Therapeutics Corp Warrant positions in Q4 2025 and 0 closed out, a net change of +1 holder.
  • The largest BriaCell Therapeutics Corp Warrant seller in Q4 2025 was Sabby Management, an estimated $40.4K sold.

Based on aggregated 13F filings for Q4 2025.